Recruiting Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer NCT06900595 Conditions Adenocarcinoma, Adrenal Cortex Diseases, Adrenal Cortex Neoplasms, +16 more Locations UC San Diego Moores Cancer Center — La Jolla, California, United States Valley Children's Hospital — Madera, California, United States UCHealth University of Colorado Hospital — Aurora, Colorado, United States Lurie Children's Hospital-Chicago — Chicago, Illinois, United States View all 77 locations View more locations Show fewer locations Loading locations... View Trial Details
